ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)

ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)

Commentaires

Articles les plus consultés